Tandem Diabetes Care Secures $75 Million in Funding to Advance Revolutionary Insulin Delivery Systems

Tandem Diabetes Care, a pioneering force in insulin delivery and diabetes technology based in San Diego, has successfully secured $75 million in a significant funding round aimed at enhancing its cutting-edge automated insulin delivery systems. Renowned for its innovative products like the Tandem Mobi system and the t:slim X2 insulin pump, equipped with the industry-leading Control-IQ advanced hybrid closed-loop technology, Tandem is committed to improving the lives of individuals managing diabetes. This investment underscores Tandem's mission to not only alleviate the challenges associated with diabetes management but also to unlock new possibilities for patients, caregivers, and healthcare providers alike. Recognized as the #1 recommended insulin pump brand by users for four consecutive years, Tandem’s reputation for excellence is firmly established, as noted in the dQ&A US Diabetes Connections Patient Panel Report. The funding will be strategically allocated to expand research and development efforts, drive innovations in product offerings, enhance customer support, and broaden market reach. As diabetes continues to affect millions globally, Tandem Diabetes Care remains steadfast in its commitment to transforming diabetes management through advanced technology and personal empowerment. For more information about Tandem’s advanced diabetes solutions and to stay updated on upcoming innovations, visit their website at tandemdiabetes.com.